Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mooney

Showing results (151-160 of 177) with videos related to

Pageof 18
Sort By:
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
Biological Chemistry|January 15, 2004
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1Brian D Green, Victor A Gault, Nigel Irwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2005
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetesNigel Irwin, Brian D Green, Mark H Mooney, et al.
Journal of Molecular Endocrinology|December 11, 2003
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.
Journal of Medicinal Chemistry|May 9, 2009
Benzylguanidines and other galegine analogues inducing weight loss in miceGeoffrey D Coxon, Brian L Furman, Alan L Harvey, et al.
Biological Chemistry|April 23, 2004
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analoguesBrian D Green, Victor A Gault, Mark H Mooney, et al.
Journal of Craniovertebral Junction & Spine|October 20, 2023
Patient perception of spinal cord injury through social media: An analysis of 703 Instagram and 117 Twitter postsAvi A Gajjar, Anthony Huy Dinh Le, Rachel Jacobs, et al.
Neoplasia (New York, N.Y.)|October 7, 2005
Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancersMatthias P A Ebert, Suzanne H Mooney, Lori Tonnes-Priddy, et al.
Analytical and Bioanalytical Chemistry|November 16, 2012
Effect-based proteomic detection of growth promoter abuseTerence F McGrath, Jeroen A van Meeuwen, Anne-Cécile Massart, et al.
Journal of Racial and Ethnic Health Disparities|June 6, 2026
Reducing Inequalities in Stroke Events-Hemorrhagic Disparities (RISE-HD): a 10-Year Longitudinal Study in FloridaNatália Vasconcellos de Oliveira Souza, Alejandra Díaz-Rohena, Amra Sakusic, et al.
Pageof 18

Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
Biological Chemistry|January 15, 2004
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1Brian D Green, Victor A Gault, Nigel Irwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2005
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetesNigel Irwin, Brian D Green, Mark H Mooney, et al.
Journal of Molecular Endocrinology|December 11, 2003
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivoB D Green, V A Gault, M H Mooney, et al.
Journal of Medicinal Chemistry|May 9, 2009
Benzylguanidines and other galegine analogues inducing weight loss in miceGeoffrey D Coxon, Brian L Furman, Alan L Harvey, et al.
Biological Chemistry|April 23, 2004
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analoguesBrian D Green, Victor A Gault, Mark H Mooney, et al.
Journal of Craniovertebral Junction & Spine|October 20, 2023
Patient perception of spinal cord injury through social media: An analysis of 703 Instagram and 117 Twitter postsAvi A Gajjar, Anthony Huy Dinh Le, Rachel Jacobs, et al.
Neoplasia (New York, N.Y.)|October 7, 2005
Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancersMatthias P A Ebert, Suzanne H Mooney, Lori Tonnes-Priddy, et al.
Analytical and Bioanalytical Chemistry|November 16, 2012
Effect-based proteomic detection of growth promoter abuseTerence F McGrath, Jeroen A van Meeuwen, Anne-Cécile Massart, et al.
Journal of Racial and Ethnic Health Disparities|June 6, 2026
Reducing Inequalities in Stroke Events-Hemorrhagic Disparities (RISE-HD): a 10-Year Longitudinal Study in FloridaNatália Vasconcellos de Oliveira Souza, Alejandra Díaz-Rohena, Amra Sakusic, et al.
Pageof 18